Prostate cancer is the 3rd lethal type of cancer in the United States. Its diagnostic and stage assessment is done by histological analysis of microbiopsy, imagery, and serum marker evaluation. ()
Prostate specific membrane antigen () a membrane glycoprotein also known as Glutamate carboxypeptidase II (GCPII) is highly associated tumorigenicity of prostate cancer. Its overexpression in neovascularized tumor tissue has also been reported in various types of cancer. () Different antibodies and ligands targeting have been developed during the last 15 years, but their use in diagnostic is more recent. Briefly, gallium 68 labeled ligands are used to label positive cells in patients and then the detection is done by PET/CT. () is an interesting target for a theranostic approaches, a combination of therapy therapy and diagnostic, and some ligands were developed over the years with this idea in mind. Following this concept the specific ligands discovered could be used for the detection, when radio labeled, and the treatment of the positive patients when coupled with a cytotoxic compound. ()
andhave been developed against an epitope located on the extracellular portion of the . These antibodies have been fully characterized and have shown an excellent specificity to in a live LNCaP cell line model. ()